Mass Spectrometry Amyloid Typing Is Reproducible across Multiple Organ Sites

Table 1

Clinical and laboratory characteristics of patients.

Case	Sex	Age	Clinical Diagnosis	Serum Protein	FLC κ	FLC λ	FLC	Cardiomyopathy	Nephropathy
					[mg/L]	[mg/L]	κ/λ ratio
1	M	68	MGUS	IgG κ	449.5	91.0	4.939	Mayo 3	NS + RI
2	M	58	MM	IgD κ	241. 5	1	241.5	Mayo 3	NS + RI
3	M	49	MGUS	κ	2114.3	36.7	57.61	Mayo 3	NS + RI
4	M	70	MM	κ	906.3	16.5	54.90	Mayo 3	NS + RI
5	F	78	MM	κ	1588.2	24.4	65.09	Mayo 3	NS
6	M	63	MGUS	λ	18.2	593.4	0.031	Mayo 3	NS + RI
7	F	75	MGUS	IgA λ	18.7	284.7	0.066	Mayo 3	NS + RI
8	M	84	MGUS	IgA λ	47.2	84.1	0.561	Mayo 3	NS + RI
9	F	67	MGUS	λ	21.1	70.1	0.302	Mayo 3	NS + RI
10	M	77	-	ND	ND	ND	ND	Mayo 3	-
11	M	49	MGUS	λ	22.6	495.1	0.046	Mayo 3	NS

FLC, free light chains; MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; ND, not determined; NS, nephrotic syndrome; RI, renal insufficiency (creatinine level ≥130 μmol/L); Mayo, Mayo Clinic staging system (1–3) based on troponin T and NT-proBNP levels.
Reference range: FLC κ: 3.3–19.4 mg/L; FLC λ: 5.7–26.3 mg/L; FLC κ/λ ratio 0.26–1.65.